Concepedia

Phillip S. Pang

PS

57

Publications

10.5K

Citations

39

H-Index

2002

Active since

Affiliations

Gilead Sciences (United States)(Current)

The University of Texas Health Science Center at San Antonio

Texas Liver Institute

Goethe University Frankfurt

University of Pennsylvania

Phillip S. Pang is an author at Gilead Sciences (United States) specializing in medicine, viral hepatitis, and hepatitis.

ORCID

Top concepts

Publications per year

2002–2024

57

Publications

57

Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection

Nezam H. Afdhal, Stefan Zeuzem, Paul Y. Kwo et al. · New England Journal of Medicine · 2014 · 1.7K citations · Full text

Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection

Nezam H. Afdhal, K. Rajender Reddy, David R. Nelson et al. · New England Journal of Medicine · 2014 · 1.3K citations

Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis

Kris V. Kowdley, Stuart C. Gordon, K. Rajender Reddy et al. · New England Journal of Medicine · 2014 · 1.1K citations · Full text

Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease

Michael Charlton, Gregory T. Everson, Steven L. Flamm et al. · Gastroenterology · 2015 · 795 citations · Full text

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial

Eric Lawitz, Fred Poordad, Phillip S. Pang et al. · The Lancet · 2013 · 546 citations

, , +8

Rows per page

1–5 of 57